Loading clinical trials...

Gypenosides Treatment for Optic Neuritis | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Gypenosides Treatment for Optic Neuritis

Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial

NCT02976766•First Affiliated Hospital of Guangxi Medical University

Summary

The purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Male and female Chinese patients aged ≥18 to ≤60 years
•2. Patients with a first episode of optic neuritis in the eye of interest
•3. First symptoms of optic neuritis ≤28 days prior to the first administration of investigational product
•4. Best corrected visual acuity in the eye of interest ≤0.8

Exclusion Criteria

•1. Pre-existing multiple sclerosis MS or NMO
•2. Refractive media opacity
•3. Hyperopia \>5 diopters, myopia \<-5 diopters, or astigmatism \>3 diopters
•4. Active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, infection with HIV or syphilis, or any other conditions potentially interfering treatment trial
•5. Other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc)
•6. Existing other retina or optic nerve diseases
•7. Pregnant or females who plan to be pregnant during study

Locations (1)

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

Key Dates

Start Date

February 4, 2017

Primary Completion Date

December 31, 2020

Completion Date

December 31, 2020

Last Updated

December 19, 2025

Enrollment

ACTUAL participants

Conditions

Optic Neuritis

Interventions

Gypenosides

DRUG

Placebo

DRUG

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT07100990

Optic NeuritisMyelitis+1 more

View study

RECRUITINGPHASE2

Efgartigimod for the Treatment of Acute Optic Neuritis

NCT06453694

Optic Neuritis

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Gypenosides Treatment for Optic Neuritis

Inclusion Criteria

Exclusion Criteria

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

Efgartigimod for the Treatment of Acute Optic Neuritis

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Visual (Path)Ways in Multiple Sclerosis - Part II

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders